P069 Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study)

S. Carson; Parniya Arooj; Gisli G. Einarsson; A. Marshall; J. Carson; Kevin F. Deasy; Yvonne Mccarthy; Tamara Vagg; J. Dorgan; M. McCarthy; C.  Flemming; Joe Eustace; D. Murphy; Deirdre F. Gilpin; J. Stuart Elborn; Tunney MM; Barry James Plant

doi:10.1016/s1569-1993(23)00444-7

P069 Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study)

S. Carson
, Parniya Arooj
, Gisli G. Einarsson
, A. Marshall
, J. Carson
, Kevin F. Deasy
, Yvonne Mccarthy
, Tamara Vagg
, J. Dorgan
, M. McCarthy
, C. Flemming
, Joe Eustace
, D. Murphy
, Deirdre F. Gilpin
, J. Stuart Elborn
, Tunney MM
, Barry James Plant

HRB Clinical Research Facility

Queen's University Belfast
Cork Centre for Cystic Fibrosis (3CF)
HRB Clinical Research Facility Cork

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

CFTR modulator therapy with Orkambi® (lumacaftor/ivacaftor) reduces the rate of decline of FEV1 in people with cystic fibrosis (PwCF) homozygous for the F508del mutation. However, the effect of Orkambi® on the composition and structure of the CF airway microbiota remains unclear. In this study, we determined the effect of therapy with Orkambi® on lung microbiota composition.

Original language	English
Pages (from-to)	s84
Journal	Journal of Cystic Fibrosis
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/s1569-1993(23)00444-7
Publication status	Published - Jun 2023
Event	46th European Cystic Fibrosis Conference - Vienna, Austria Duration: 7 Jun 2023 → 10 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Sputum
16S ribosomal RNA
Amplicon
Microbiology
Medicine
Amplicon sequencing
Ribosomal RNA
Biology
Bacteria
Polymerase chain reaction
Gene
Genetics
Pathology
Tuberculosis

Access to Document

10.1016/s1569-1993(23)00444-7Licence: Unspecified

Cite this

Carson, S., Arooj, P., Einarsson, G. G., Marshall, A., Carson, J., Deasy, K. F., Mccarthy, Y., Vagg, T., Dorgan, J., McCarthy, M., Flemming, C., Eustace, J., Murphy, D., Gilpin, D. F., Elborn, J. S., MM, T., & Plant, B. J. (2023). P069 Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study). Journal of Cystic Fibrosis, 22(2), s84. https://doi.org/10.1016/s1569-1993(23)00444-7

@article{9b1958fcb0a24c8987518706dbd4c876,

title = "P069 Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study)",

abstract = "CFTR modulator therapy with Orkambi{\textregistered} (lumacaftor/ivacaftor) reduces the rate of decline of FEV1 in people with cystic fibrosis (PwCF) homozygous for the F508del mutation. However, the effect of Orkambi{\textregistered} on the composition and structure of the CF airway microbiota remains unclear. In this study, we determined the effect of therapy with Orkambi{\textregistered} on lung microbiota composition.",

keywords = "Sputum, 16S ribosomal RNA, Amplicon, Microbiology, Medicine, Amplicon sequencing, Ribosomal RNA, Biology, Bacteria, Polymerase chain reaction, Gene, Genetics, Pathology, Tuberculosis",

author = "S. Carson and Parniya Arooj and Einarsson, \{Gisli G.\} and A. Marshall and J. Carson and Deasy, \{Kevin F.\} and Yvonne Mccarthy and Tamara Vagg and J. Dorgan and M. McCarthy and C. Flemming and Joe Eustace and D. Murphy and Gilpin, \{Deirdre F.\} and Elborn, \{J. Stuart\} and Tunney MM and Plant, \{Barry James\}",

year = "2023",

month = jun,

doi = "10.1016/s1569-1993(23)00444-7",

language = "English",

volume = "22",

pages = "s84",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier B.V.",

number = "2",

note = "46th European Cystic Fibrosis Conference ; Conference date: 07-06-2023 Through 10-06-2023",

}

Carson, S, Arooj, P, Einarsson, GG, Marshall, A, Carson, J, Deasy, KF, Mccarthy, Y , Vagg, T, Dorgan, J, McCarthy, M, Flemming, C, Eustace, J, Murphy, D, Gilpin, DF, Elborn, JS, MM, T & Plant, BJ 2023, 'P069 Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study)', Journal of Cystic Fibrosis, vol. 22, no. 2, pp. s84. https://doi.org/10.1016/s1569-1993(23)00444-7

TY - JOUR

T1 - P069 Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study)

AU - Carson, S.

AU - Arooj, Parniya

AU - Einarsson, Gisli G.

AU - Marshall, A.

AU - Carson, J.

AU - Deasy, Kevin F.

AU - Mccarthy, Yvonne

AU - Vagg, Tamara

AU - Dorgan, J.

AU - McCarthy, M.

AU - Flemming, C.

AU - Eustace, Joe

AU - Murphy, D.

AU - Gilpin, Deirdre F.

AU - Elborn, J. Stuart

AU - MM, Tunney

AU - Plant, Barry James

PY - 2023/6

Y1 - 2023/6

N2 - CFTR modulator therapy with Orkambi® (lumacaftor/ivacaftor) reduces the rate of decline of FEV1 in people with cystic fibrosis (PwCF) homozygous for the F508del mutation. However, the effect of Orkambi® on the composition and structure of the CF airway microbiota remains unclear. In this study, we determined the effect of therapy with Orkambi® on lung microbiota composition.

AB - CFTR modulator therapy with Orkambi® (lumacaftor/ivacaftor) reduces the rate of decline of FEV1 in people with cystic fibrosis (PwCF) homozygous for the F508del mutation. However, the effect of Orkambi® on the composition and structure of the CF airway microbiota remains unclear. In this study, we determined the effect of therapy with Orkambi® on lung microbiota composition.

KW - Sputum

KW - 16S ribosomal RNA

KW - Amplicon

KW - Microbiology

KW - Medicine

KW - Amplicon sequencing

KW - Ribosomal RNA

KW - Biology

KW - Bacteria

KW - Polymerase chain reaction

KW - Gene

KW - Genetics

KW - Pathology

KW - Tuberculosis

UR - https://openalex.org/W4379981537

U2 - 10.1016/s1569-1993(23)00444-7

DO - 10.1016/s1569-1993(23)00444-7

M3 - Meeting abstract

SN - 1569-1993

VL - 22

SP - s84

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 2

T2 - 46th European Cystic Fibrosis Conference

Y2 - 7 June 2023 through 10 June 2023

ER -

P069 Effect of Orkambi therapy on the lung microbiota in people with cystic fibrosis (PwCF) over the first 12 months of therapy (ROCK Study)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this